These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 35084268)

  • 21. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.
    Oyedele AK; Ogunlana AT; Boyenle ID; Ibrahim NO; Gbadebo IO; Owolabi NA; Ayoola AM; Francis AC; Eyinade OH; Adelusi TI
    Mol Divers; 2023 Aug; 27(4):1795-1807. PubMed ID: 36271195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutics Targeting Mutant KRAS.
    Thein KZ; Biter AB; Hong DS
    Annu Rev Med; 2021 Jan; 72():349-364. PubMed ID: 33138715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS mutation: from undruggable to druggable in cancer.
    Huang L; Guo Z; Wang F; Fu L
    Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
    Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
    J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay.
    Swiatnicki M; Engel L; Shrestha R; Alves J; Goueli SA; Zegzouti H
    SLAS Discov; 2022 Jun; 27(4):249-257. PubMed ID: 35288294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine.
    Sahin IH; Saridogan T; Ayasun R; Syed MP; Gorantla V; Malhotra M; Thomas R; Rhee J; Zhang J; Hsu D; Singhi AD; Saeed A
    JCO Oncol Pract; 2024 Oct; 20(10):1336-1347. PubMed ID: 38739872
    [No Abstract]   [Full Text] [Related]  

  • 28. Drugging KRAS: current perspectives and state-of-art review.
    Parikh K; Banna G; Liu SV; Friedlaender A; Desai A; Subbiah V; Addeo A
    J Hematol Oncol; 2022 Oct; 15(1):152. PubMed ID: 36284306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting KRAS mutant cancers: from druggable therapy to drug resistance.
    Zhu C; Guan X; Zhang X; Luan X; Song Z; Cheng X; Zhang W; Qin JJ
    Mol Cancer; 2022 Aug; 21(1):159. PubMed ID: 35922812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.
    Jiang Z; Li Y; Zhou X; Wen J; Zheng P; Zhu W
    Bioorg Med Chem; 2024 Feb; 100():117627. PubMed ID: 38310752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
    Nyíri K; Koppány G; Vértessy BG
    Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of PROTACS degrading KRAS and SOS1.
    Hamilton G; Eggerstorfer MT; Stickler S
    Oncol Res; 2024; 32(8):1257-1264. PubMed ID: 39055890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
    Hofmann MH; Gmachl M; Ramharter J; Savarese F; Gerlach D; Marszalek JR; Sanderson MP; Kessler D; Trapani F; Arnhof H; Rumpel K; Botesteanu DA; Ettmayer P; Gerstberger T; Kofink C; Wunberg T; Zoephel A; Fu SC; Teh JL; Böttcher J; Pototschnig N; Schachinger F; Schipany K; Lieb S; Vellano CP; O'Connell JC; Mendes RL; Moll J; Petronczki M; Heffernan TP; Pearson M; McConnell DB; Kraut N
    Cancer Discov; 2021 Jan; 11(1):142-157. PubMed ID: 32816843
    [No Abstract]   [Full Text] [Related]  

  • 35. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.
    Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
    Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
    Chen H; Smaill JB; Liu T; Ding K; Lu X
    J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
    Tang D; Kroemer G; Kang R
    Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.
    Tripathi P; Kumari R; Pathak R
    Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Mutated KRAS Genes to Treat Solid Tumours.
    Krishnan T; Roberts-Thomson R; Broadbridge V; Price T
    Mol Diagn Ther; 2022 Jan; 26(1):39-49. PubMed ID: 34914038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.